WO2022078428A8 - 作为脯氨酰羟化酶抑制剂的化合物及其制备方法 - Google Patents
作为脯氨酰羟化酶抑制剂的化合物及其制备方法 Download PDFInfo
- Publication number
- WO2022078428A8 WO2022078428A8 PCT/CN2021/123750 CN2021123750W WO2022078428A8 WO 2022078428 A8 WO2022078428 A8 WO 2022078428A8 CN 2021123750 W CN2021123750 W CN 2021123750W WO 2022078428 A8 WO2022078428 A8 WO 2022078428A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- prolyl hydroxylase
- preparation
- method therefor
- hydroxylase inhibitor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
提供一种作为脯氨酰羟化酶抑制剂的化合物及其制备方法，属于医药技术领域。所述化合物如式I所示，具有脯氨酰羟化酶抑制活性，可用于治疗由脯氨酰羟化酶活性介导的疾病，如肾性贫血等。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202180066355.9A CN116472266A (zh) | 2020-10-16 | 2021-10-14 | 作为脯氨酰羟化酶抑制剂的化合物及其制备方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011114555 | 2020-10-16 | ||
| CN202011114555.0 | 2020-10-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2022078428A1 WO2022078428A1 (zh) | 2022-04-21 |
| WO2022078428A8 true WO2022078428A8 (zh) | 2023-03-30 |
Family
ID=81207690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/123750 WO2022078428A1 (zh) | 2020-10-16 | 2021-10-14 | 作为脯氨酰羟化酶抑制剂的化合物及其制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116472266A (zh) |
| WO (1) | WO2022078428A1 (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3026044B8 (en) * | 2006-06-26 | 2018-12-19 | Akebia Therapeutics, Inc. | Prolyl hydroxylase inhibitors and methods of use |
| WO2019028150A1 (en) * | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| CN107417605A (zh) * | 2017-08-02 | 2017-12-01 | 江苏艾立康药业股份有限公司 | 作用于脯氨酰羟化酶的吡啶衍生化合物 |
| CN109593084B (zh) * | 2019-01-23 | 2021-09-28 | 中国药科大学 | 脯氨酰羟化酶小分子光敏前药及其制备方法与应用 |
| CN111349077B (zh) * | 2019-02-02 | 2022-06-28 | 杭州华东医药集团新药研究院有限公司 | 一种哒嗪衍生物及其制备方法和医药用途 |
-
2021
- 2021-10-14 CN CN202180066355.9A patent/CN116472266A/zh active Pending
- 2021-10-14 WO PCT/CN2021/123750 patent/WO2022078428A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN116472266A (zh) | 2023-07-21 |
| WO2022078428A1 (zh) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012054A (es) | Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion. | |
| PH12020551184A1 (en) | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | |
| MX2019004018A (es) | Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica. | |
| BR112015025413A2 (pt) | inibidores de proteína cinase | |
| MD20140047A2 (ro) | Inhibitori ai protein kinazei | |
| SG11201901061QA (en) | Heterocyclic compound | |
| EA200970680A1 (ru) | N-замещенные производные глицина: ингибиторы гидроксилаз | |
| CL2015001068A1 (es) | Inhibidores heteroarilo de pde4 | |
| EA201291317A1 (ru) | Тетрагидропиридопиримидиновые производные | |
| AU2011201462B2 (en) | Method of Administering Pirfenidone Therapy | |
| WO2008076427A3 (en) | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | |
| NZ598242A (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
| MY153880A (en) | Proline derivatives as cathepsin inhibitors | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| MX2009013565A (es) | Derivados de azapeptidos. | |
| WO2018125961A8 (en) | Poly-adp ribose polymerase (parp) inhibitors | |
| CA2881554C (en) | Methods for inhibiting fascin | |
| MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
| WO2022217123A3 (en) | Combination therapies with cbl-b inhibitor compounds | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| UA107721C2 (ru) | Способ получения производной 4-(2-оксопиперидин-1-ил)масляной кислоты как промежуточного соединения для синтезирования медикамента | |
| WO2022078428A8 (zh) | 作为脯氨酰羟化酶抑制剂的化合物及其制备方法 | |
| WO2022221528A3 (en) | Kras g12c inhibitors | |
| PH12021550557A1 (en) | Furo[3,4-b]pyrrole-containing btk inhibitor | |
| WO2023064669A3 (en) | Inhibitors of the mtdh-snd1 protein complex for cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21879471 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202180066355.9 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21879471 Country of ref document: EP Kind code of ref document: A1 |